<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287803</url>
  </required_header>
  <id_info>
    <org_study_id>20191107100</org_study_id>
    <nct_id>NCT04287803</nct_id>
  </id_info>
  <brief_title>Prehospital Analgesia in Adults Using Inhaled Methoxyflurane : A Feasibility Study</brief_title>
  <official_title>Prehospital Analgesia in Adults Using Inhaled (PAIN) Methoxyflurane : A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is common and can contribute to both psychological and physiological effects if not&#xD;
      treated. Currently primary care paramedics have limited selections within their pain&#xD;
      management tool box. This contributes to inadequate pain management. Methoxyflurane is a&#xD;
      safe, easy and effective choice in prehospital management of pain. The impact of this&#xD;
      feasibility trial, will hope to inform the larger multi-centred trial and then support the&#xD;
      implementation of out-of-hospital Canadian National Guidelines for prehospital pain control,&#xD;
      enabling paramedics to provide rapid, effective prehospital pain relief to patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single-centred prehospital prospective observational feasibility study to&#xD;
      evaluate the ability to perform a multicentred step wedge design trial. The feasibility&#xD;
      outcomes will provide evidence for the development of the multicentred study and will capture&#xD;
      clinical metrics to inform this larger study. A waver of consent will be sought from the&#xD;
      ethics board with participation consent for paramedics understanding the risk of using a gas&#xD;
      for analgesia. Patient &gt;= 18 years of age with traumatic pain with a verbal score &gt;= to 4&#xD;
      will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Feasibility study to inform the multicentred prehospital prospective observational step wedge design trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to ethics approval for single site</measure>
    <time_frame>from ethics submission up to 90 days</time_frame>
    <description>Target: ,&lt;= 3 months (90 days) from ethics submission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to readiness to initiate the clinical trial</measure>
    <time_frame>From ethics approval up to 90 days</time_frame>
    <description>Target, &lt;= 3 months (90 days) from ethics approval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of outcome data collected</measure>
    <time_frame>For length of study, up to 100 patients</time_frame>
    <description>Target: 100% of data captured in &gt;90% cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study protocol compliance by paramedics</measure>
    <time_frame>For length of study, up to 100 patients</time_frame>
    <description>Target, &gt;= 80%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal numeric pain rating score (0-10) initial and recorded every 5 minutes</measure>
    <time_frame>For length of study, up to 100 patients specifically from patient contact to transfer of care in the emergency department</time_frame>
    <description>Degree of change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication (as defined by addition of any other pain medication after methoxyflurane administration, during paramedic care)</measure>
    <time_frame>For length of study, up to 100 patients. specifically from patient contact to transfer of care in the emergency department</time_frame>
    <description>If other medication are used to control pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transport time</measure>
    <time_frame>For length of study, up to 100 patients, specifically departure scene to arrival at hospital</time_frame>
    <description>Defined by departure from scene to arrival at hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first administration of methoxyflurane</measure>
    <time_frame>For length of study, up to 100 patients. Specifically time from patient contact to first inhalation of methoxyflurane</time_frame>
    <description>Time from first patient contact to first inhalation of methoxyflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and level of consciousness</measure>
    <time_frame>From patient contact to transfer of care</time_frame>
    <description>Vital signs including (Heart rate, Blood pressure, Respiratory rate, Oxygen saturation, Temperature, Glasgow Coma Scale (GCS))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events post administration of methoxyflurane:</measure>
    <time_frame>For length of study, up to 100 patients. Specifically from patient contact to transfer of care</time_frame>
    <description>Example: any advanced airway interventions, oxygen requirement (oxygen saturations &lt;94%), drop in blood pressure by 40% and/or &lt;90 systolic, complaints of nausea or vomiting, malignant hyperthermia reaction).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pain, Acute</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methoxyflurane will be introduced and data will be captured to inform future multicentred step wedge design study. (This study is a feasibility study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores &gt;=4</description>
    <arm_group_label>intervention Arm</arm_group_label>
    <other_name>Penthrox</other_name>
    <other_name>Penthrane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;=18 years of age&#xD;
&#xD;
          -  Acute pain from traumatic injury&#xD;
&#xD;
          -  numeric pain score &gt;=4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or sensitivity to methoxyflurane&#xD;
&#xD;
          -  History or family history of malignant hyperthermia&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Known renal impairment&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Methoxyflurane use within previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Austin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael A Austin, MD</last_name>
    <phone>613 737-7228</phone>
    <email>maustin@toh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juiie Sinclair</last_name>
    <phone>613-737-7228</phone>
    <email>jusinclair@rppeo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr Michael A Austin</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A Austin, MD</last_name>
      <phone>613-737-7228</phone>
      <email>maustin@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie SInclair</last_name>
      <phone>63-737-7228</phone>
      <email>jusinclair@rppeo.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prehospital</keyword>
  <keyword>paramedic</keyword>
  <keyword>ambulance</keyword>
  <keyword>methoxyflurane</keyword>
  <keyword>Penthrox</keyword>
  <keyword>Penthrane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified data for primary and secondary outcome maybe available to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

